share_log

金斯瑞生物科技：翌日披露報表

GENSCRIPT BIO: Next Day Disclosure Return

香港交易所 ·  Apr 2 20:57
Summary by Futu AI
金斯瑞生物科技於2024年4月2日根據其於2021年8月23日採納的限制性股份獎勵計劃，發行及配發了139,176股新普通股。此次發行將公司的已發行股本從2,123,888,494股增加至2,124,027,670股，增幅為0.0066%。新發行股份的發行價為每股HKD 0.00778，較上一個營業日的收市價HKD 14.5折讓了99.95%。公司確認所有相關的法律及上市規定已遵守，並且已收取全部應得款項。
金斯瑞生物科技於2024年4月2日根據其於2021年8月23日採納的限制性股份獎勵計劃，發行及配發了139,176股新普通股。此次發行將公司的已發行股本從2,123,888,494股增加至2,124,027,670股，增幅為0.0066%。新發行股份的發行價為每股HKD 0.00778，較上一個營業日的收市價HKD 14.5折讓了99.95%。公司確認所有相關的法律及上市規定已遵守，並且已收取全部應得款項。
Kingsway Biotechnology issued and issued 139,176 shares of New Ordinary Shares on April 2, 2024 pursuant to its Restricted Share Award Scheme adopted on August 23, 2021. The issuance increased the Company's issued share capital from 2,123,888,494 shares to 2,124,027,670 shares, an increase of 0.0066%. The issue price of the newly issued shares was HKD 0.00778 per share, representing a 14.5% discount on the previous business day's closing price of HKD 99.95%. The Company confirms that all relevant laws and listing requirements have been complied with and that all monies due have been received.
Kingsway Biotechnology issued and issued 139,176 shares of New Ordinary Shares on April 2, 2024 pursuant to its Restricted Share Award Scheme adopted on August 23, 2021. The issuance increased the Company's issued share capital from 2,123,888,494 shares to 2,124,027,670 shares, an increase of 0.0066%. The issue price of the newly issued shares was HKD 0.00778 per share, representing a 14.5% discount on the previous business day's closing price of HKD 99.95%. The Company confirms that all relevant laws and listing requirements have been complied with and that all monies due have been received.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.